Parsippany, NJ – June 26, 2023 – Ferring Pharmaceuticals today announced it will make the intravesical gene-therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) available…
Approval of Prior-Approval Supplement will help to ensure the future, long-term supply and clinical activities for Ferring’s novel intravesical gene…
The primary endpoint was met: SI-6603 showed statistically significant improvement in worst leg pain score versus control at 13 weeks…
Data presentations highlight Ferring’s microbiome leadership and commitment to ongoing research Analyses review safety and efficacy data across various patient…
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age…
National Infertility Awareness Week® seeks to inspire, educate and activate the fertility community to speak up about infertility to help…
Parsippany, NJ, USA – April 18, 2023 – Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA™…
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age…
Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and…
Ferring’s novel first-in-class REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years…